Home Cart Sign in  
Chemical Structure| 22427-39-0 Chemical Structure| 22427-39-0

Structure of Ginsenoside Rg1
CAS No.: 22427-39-0

Chemical Structure| 22427-39-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ginsenoside Rg1, a natural product isolated and purified from the roots of Panax ginseng C. A. Mey., is a functional ligand of glucocorticoid receptor(GR) that can boost the production of insulin receptors, stimulates the creation of new blood vessels and wound healing, relaxes and widens blood vessels and lowers blood pressure, and is a potent phytoestrogen with estrogen-like activity.

Synonyms: Panaxoside Rg1; Panaxoside A; Sanchinoside Rg1

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ginsenoside Rg1

CAS No. :22427-39-0
Formula : C42H72O14
M.W : 801.01
SMILES Code : C[C@@]12[C@@]([H])([C@](C)([C@]3([C@H](C2)O[C@@H]4O[C@@H]([C@H]([C@@H]([C@H]4O)O)O)CO)[H])CC[C@@H](C3(C)C)O)C[C@H]([C@]5([C@]1(CC[C@@H]5[C@@](C)(O[C@@H]6O[C@@H]([C@H]([C@@H]([C@H]6O)O)O)CO)CC/C=C(C)\C)C)[H])O
Synonyms :
Panaxoside Rg1; Panaxoside A; Sanchinoside Rg1
MDL No. :MFCD00210293
InChI Key :YURJSTAIMNSZAE-HHNZYBFYSA-N
Pubchem ID :441923

Safety of Ginsenoside Rg1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Primary RGCs 1, 10, 30 μM 1 week Promoted neurite growth of primary RGCs PMC10920000
HeLa cells 10 μM 10 hours Ginsenoside Rg1 reduced cancer cell proliferation through inducing mitotic arrest. PMC9120780
RGC-5s cells 1, 10, 30 μM 2 days Promoted neurite growth and synaptic plasticity of RGC-5s cells PMC10920000
HepG2 cells 0.1, 1 or 10 μM 2 hours To study the effect of Rg1 on the binding of Akt to FoxO1, results showed that Rg1 promoted Akt binding to FoxO1 and inhibited FoxO1 nuclear translocation. PMC5667421
PC12 cells 0.01 –1 μM 24 hours Rg1 significantly attenuated OGD/R-induced cell injury, accompanied by prolonging nuclear accumulation of Nrf2, enhancing the transcriptional activity of Nrf2, and promoting the expression of ARE-target genes. PMC6318278
Hepatic stellate cells 50 μM 24 hours Inhibited HSC proliferation and collagen expression, reducing liver fibrosis via EMT pathway inhibition PMC10310870
HT22 cells 5, 10 μM 24 hours To study the effect of Rg1 on calcium overload induced by OGD/R in HT22 cells, the results showed that Rg1 could inhibit calcium overload and resist the imbalance of calcium homeostasis. PMC9270650
Pulmonary artery smooth muscle cells (PASMCs) 20 μM 24 hours Ginsenoside Rg1 inhibits hypoxia-induced PASMCs proliferation, inflammation, and fibrosis by downregulating the calpain-1/STAT3 signaling pathway. PMC11258379
Rat bone marrow-derived macrophages (BMDMs) 1, 2, 4 μM 24 hours To investigate the effects of Rg1 on AIM2 inflammasome activation and macrophage polarization. Results showed that Rg1 significantly inhibited AIM2 inflammasome activation and reduced M1 macrophage polarization. PMC11583468
Cardiac fibroblasts 10 μM 24 hours Ginsenoside Rg1 reduced collagen I and III mRNA expression and inhibited cardiac fibroblast proliferation. PMC8569322
Cardiomyocytes 10 μM 24 hours Ginsenoside Rg1 inhibited stretch-induced cardiomyocyte hypertrophy and reduced ANP and BNP mRNA expression. PMC8569322
Neuronal cells 40 μM 48 hours To assess the effect of Rg1 pretreatment on EV secretion from neuronal cells, results showed that Rg1 pretreatment increased EV release. PMC11336912
MC38 cells 100 μM Inhibit PD-1/PD-L1 binding PMC10770033
RPE1 cells 10 μM Ginsenoside Rg1 did not inhibit H3T3ph in normal cells. PMC9120780
DC2.4 cells 2.5–100 μM 24 hours Promoted DC2.4 cell maturation and upregulated CD40 and CD86 expression PMC11481235

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Traumatic brain injury model Intraperitoneal injection 5, 10, 15 mg/kg 30 minutes and 24 hours after injury Evaluated the protective effect of Rg1 on traumatic brain injury, results showed that Rg1 significantly improved neurological deficits, brain edema and BBB permeability PMC8642604
C57BL/6J mice High-fat diet-induced obese Mice model Oral 50 mg/kg Once daily for 8 weeks To investigate the effect of Rg1 on blood glucose and hepatic glucose production in high-fat diet-induced obese mice, results showed that Rg1 reduced fasting blood glucose, improved glucose tolerance, and suppressed the expression of hepatic gluconeogenesis-related enzymes. PMC5667421
C57BL/6 mice MC38 tumor xenograft lung metastasis model Intraperitoneal injection 100 mg/kg Once daily for four weeks Inhibit colon cancer lung metastasis and activate CD8 T cells PMC10770033
Sprague-Dawley rats Transient middle cerebral artery occlusion (tMCAO) model Intraperitoneal injection 20 mg/kg Single dose, lasting for 24 hours Rg1 significantly alleviated ischemic injury and activated the Nrf2/ARE pathway. The protective effects of Rg1 were abolished by injecting AAV-HIF-miR-144-shRNA into the predicted ischemic penumbra. PMC6318278
C57BL/6 mice 3-nitropropionic acid-induced Huntington's disease model Oral 10, 20, 40 mg/kg Once daily for 5 days Ginsenoside Rg1 exerts neuroprotective effects in the striatum by suppressing MAPKs and NF-κB pathways PMC8379213
5XFAD mice Alzheimer's disease model Intraperitoneal injection 10 mg/kg Once daily for 30 consecutive days Rg1 restores mitophagy and ameliorates memory deficits in the AD Mice model through the PINK1-Parkin pathway. PMC10214288
C57BL/6J mice CCl4-induced liver fibrosis model Oral 40 mg/kg Twice a week for 8 weeks Significantly reduced CCl4-induced liver fibrosis, decreased collagen deposition and a-SMA expression PMC10310870
C57/BL mice Type 2 diabetes model Gavage 1, 5 or 10 mg/kg 8 weeks Rg1 treatment improved memory impairment and neuronal injury, decreased ROS, IP3, and DAG levels to revert Ca2+ overload, downregulated the expressions of p-PLC, TRPC6, CN, and NFAT1 nuclear translocation, and alleviated Aβ deposition in T2DM mice. In addition, Rg1 treatment elevated the expression of PSD95 and SYN in T2DM mice, which in turn improved synaptic dysfunction. PMC10214300
ICR mice Cerebral ischemia-reperfusion injury model Gavage 5, 10 mg/kg Once daily for 5 days before ischemia and 14 days after reperfusion To study the protective effect and mechanism of Rg1 on cerebral ischemia-reperfusion injury, the results showed that Rg1 significantly improved cerebral blood flow, locomotion, and limb coordination, reduced ROS production, increased MAP2 and PSD95 expression, and decreased p-Tau, NOX2, p-PLC, CN, NFAT1, and NLRP1 expression. PMC9270650
C57BL/6 mice Hypoxia-induced pulmonary hypertension model Intragastric administration 5, 10, 20 mg/kg Once daily for four weeks Ginsenoside Rg1 ameliorates hypoxia-induced pulmonary hypertension by suppressing the calpain-1/STAT3 signaling pathway, thereby alleviating vascular remodeling, inflammation, and fibrosis. PMC11258379
Sprague-Dawley rats Myocardial ischemia/reperfusion (MI/R) injury model Intraperitoneal injection 10 and 20 mg/kg Once daily for 7 days To evaluate the cardioprotective effects of Rg1 against MI/R injury. Results showed that Rg1 dose-dependently reduced myocardial infarct size, inhibited myocardial inflammation and fibrosis, and improved cardiac function. PMC11583468
Sprague-Dawley rats Abdominal aortic constriction model Oral 12 mg/kg Once daily for 30 days Ginsenoside Rg1 alleviated AAC-induced cardiac hypertrophy and fibrosis, and improved cardiac function. PMC8569322
Sprague-Dawley rats Achilles tendinitis model Oral 15, 30, 60 mg/kg Once daily for 30 days Rg1 promotes the healing of injured tendon in AT rat model through the activation of IGF1R and MAPK signaling pathway PMC9270649

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.25mL

0.25mL

0.12mL

6.24mL

1.25mL

0.62mL

12.48mL

2.50mL

1.25mL

References

 

Historical Records

Categories